As of 2025-12-30, the Relative Valuation of Urogen Pharma Ltd (URGN) is (35.35) USD. This relative valuation is based on P/E multiples. With the latest stock price at 23.33 USD, the upside of Urogen Pharma Ltd based on Relative Valuation is -251.5%.
The range of the Relative Valuation is (15.83) - (53.39) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 4.3x - 15.2x | 9.8x |
| Forward P/E multiples | 4.5x - 16.2x | 10.4x |
| Fair Price | (15.83) - (53.39) | (35.35) |
| Upside | -167.8% - -328.9% | -251.5% |
| Date | P/E |
| 2025-12-26 | -6.55 |
| 2025-12-24 | -6.76 |
| 2025-12-23 | -6.65 |
| 2025-12-22 | -6.70 |
| 2025-12-19 | -6.48 |
| 2025-12-18 | -6.18 |
| 2025-12-17 | -6.43 |
| 2025-12-16 | -6.67 |
| 2025-12-15 | -6.50 |
| 2025-12-12 | -6.20 |
| 2025-12-11 | -6.36 |
| 2025-12-10 | -6.31 |
| 2025-12-09 | -6.45 |
| 2025-12-08 | -6.56 |
| 2025-12-05 | -6.53 |
| 2025-12-04 | -6.90 |
| 2025-12-03 | -6.92 |
| 2025-12-02 | -6.93 |
| 2025-12-01 | -8.09 |
| 2025-11-28 | -8.19 |
| 2025-11-26 | -8.36 |
| 2025-11-25 | -7.87 |
| 2025-11-24 | -7.66 |
| 2025-11-21 | -7.36 |
| 2025-11-20 | -7.06 |
| 2025-11-19 | -7.18 |
| 2025-11-18 | -6.70 |
| 2025-11-17 | -6.74 |
| 2025-11-14 | -6.76 |
| 2025-11-13 | -6.80 |
| 2025-11-12 | -7.15 |
| 2025-11-11 | -6.72 |
| 2025-11-10 | -6.58 |
| 2025-11-07 | -6.61 |
| 2025-11-06 | -6.69 |
| 2025-11-05 | -5.49 |
| 2025-11-04 | -5.63 |
| 2025-11-03 | -5.86 |
| 2025-10-31 | -5.82 |
| 2025-10-30 | -5.64 |
| 2025-10-29 | -5.62 |
| 2025-10-28 | -5.74 |
| 2025-10-27 | -5.93 |
| 2025-10-24 | -5.39 |
| 2025-10-23 | -4.93 |
| 2025-10-22 | -5.02 |
| 2025-10-21 | -5.16 |
| 2025-10-20 | -5.12 |
| 2025-10-17 | -4.82 |
| 2025-10-16 | -4.81 |